Somatostatin Receptor Type 2 (SRIF1 or SSTR2) - Pipeline Review, H2 2018
Somatostatin Receptor Type 2 (SRIF1 or SSTR2) - Pipeline Review, H2 2018
SUMMARY
According to the recently published report 'Somatostatin Receptor Type 2%li%Pipeline Review, H2 2018'; Somatostatin Receptor Type 2 (SRIF1 or SSTR2) pipeline Target constitutes close to 12 molecules.
Somatostatin Receptor Type 2 (SRIF1 or SSTR2) - Somatostatin receptor type 2 is a protein that encoded by the SSTR2 gene. Somatostatin acts at many sites to inhibit the release of many hormones and other secretory proteins. SSTR2 is expressed in highest levels in cerebrum and kidney.
The report 'Somatostatin Receptor Type 2%li%Pipeline Review, H2 2018' outlays comprehensive information on the Somatostatin Receptor Type 2 (SRIF1 or SSTR2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Somatostatin Receptor Type 2 (SRIF1 or SSTR2) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 1, 5 and 3 respectively.
Report covers products from therapy areas Hormonal Disorders, Metabolic Disorders, Oncology, Central Nervous System, Gastrointestinal, Genetic Disorders and Ophthalmology which include indications Acromegaly, Neuroendocrine Tumors, Pituitary ACTH Hypersecretion (Cushing Disease), Diabetic Retinopathy, Pituitary Tumor, Age Related Macular Degeneration, Gastric Motility Disorder, Gastrointestinal Tumor, Hypoglycemia, Ileus (Intestinal Obstruction), Medulloblastoma, Meningioma, Neuroblastoma, Neuropathic Pain (Neuralgia), Pain, Pancreatic Tumor, Polycystic Kidney Disease and Type 2 Diabetes.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
According to the recently published report 'Somatostatin Receptor Type 2%li%Pipeline Review, H2 2018'; Somatostatin Receptor Type 2 (SRIF1 or SSTR2) pipeline Target constitutes close to 12 molecules.
Somatostatin Receptor Type 2 (SRIF1 or SSTR2) - Somatostatin receptor type 2 is a protein that encoded by the SSTR2 gene. Somatostatin acts at many sites to inhibit the release of many hormones and other secretory proteins. SSTR2 is expressed in highest levels in cerebrum and kidney.
The report 'Somatostatin Receptor Type 2%li%Pipeline Review, H2 2018' outlays comprehensive information on the Somatostatin Receptor Type 2 (SRIF1 or SSTR2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Somatostatin Receptor Type 2 (SRIF1 or SSTR2) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 1, 5 and 3 respectively.
Report covers products from therapy areas Hormonal Disorders, Metabolic Disorders, Oncology, Central Nervous System, Gastrointestinal, Genetic Disorders and Ophthalmology which include indications Acromegaly, Neuroendocrine Tumors, Pituitary ACTH Hypersecretion (Cushing Disease), Diabetic Retinopathy, Pituitary Tumor, Age Related Macular Degeneration, Gastric Motility Disorder, Gastrointestinal Tumor, Hypoglycemia, Ileus (Intestinal Obstruction), Medulloblastoma, Meningioma, Neuroblastoma, Neuropathic Pain (Neuralgia), Pain, Pancreatic Tumor, Polycystic Kidney Disease and Type 2 Diabetes.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Somatostatin Receptor Type 2 (SRIF1 or SSTR2)
- The report reviews Somatostatin Receptor Type 2 (SRIF1 or SSTR2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Somatostatin Receptor Type 2 (SRIF1 or SSTR2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Somatostatin Receptor Type 2 (SRIF1 or SSTR2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Somatostatin Receptor Type 2 (SRIF1 or SSTR2) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Somatostatin Receptor Type 2 (SRIF1 or SSTR2)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Somatostatin Receptor Type 2 (SRIF1 or SSTR2) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Somatostatin Receptor Type 2 (SRIF1 or SSTR2) - Overview
Somatostatin Receptor Type 2 (SRIF1 or SSTR2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Somatostatin Receptor Type 2 (SRIF1 or SSTR2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Somatostatin Receptor Type 2 (SRIF1 or SSTR2) - Companies Involved in Therapeutics Development
Amryt Pharma plc
Crinetics Pharmaceuticals Inc
Daewoong Pharmaceutical Co Ltd
Ipsen SA
Progenics Pharmaceuticals Inc
Strongbridge Biopharma plc
Takeda Pharmaceutical Co Ltd
Zucara Therapeutics Inc
Somatostatin Receptor Type 2 (SRIF1 or SSTR2) - Drug Profiles
AP-102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CRN-00808 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CRN-01941 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Edotreotide Labeled Yttrium 90 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lanreotide acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lanreotide SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize SSTR2 and SSTR4 for Chronic Pain and Neuropathic Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize SSTR2 for Type 2 Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides to Agonize Somatostatin Receptors for Acromegaly - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
veldoreotide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
veldoreotide MR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZT-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Somatostatin Receptor Type 2 (SRIF1 or SSTR2) - Dormant Products
Somatostatin Receptor Type 2 (SRIF1 or SSTR2) - Discontinued Products
Somatostatin Receptor Type 2 (SRIF1 or SSTR2) - Product Development Milestones
Featured News & Press Releases
Jun 21, 2018: Crinetics Pharmaceuticals Awarded up to $3.2 Million in SBIR Grants for Acromegaly
Mar 12, 2018: Crinetics Pharmaceuticals Announces Upcoming Presentation on Acromegaly Drug Candiadate CRN00808 at ENDO 2018
Feb 13, 2018: Health Canada approves Ipsen Somatuline Auto gel for the treatment of carcinoid syndrome in adult patients with neuroendocrine tumors (NETs)
Feb 08, 2018: Zucara Therapeutics Receives Funding to Advance Lead Drug Candidate
Jan 15, 2018: Ipsen To Present Abstracts On lanreotide ASCO Gastrointestinal Symposium 2018
Oct 26, 2017: Crinetics Pharmaceuticals Initiates Phase 1 Study of Lead Candidate CRN00808 for Acromegaly
Sep 21, 2017: JDRF Funds Zucara Therapeutics' Approach to Preventing Hypoglycemia in People with Type 1 Diabetes
Sep 18, 2017: U.S. FDA Approves New Indication for Ipsen’s Somatuline Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome
Sep 04, 2017: Ipsen To Present Data on Somatuline at European Society of Medical Oncology congress
Jul 13, 2017: Crinetics Pharmaceuticals Awarded $2.8 Million SBIR Grant to Support Development of Acromegaly Drug Candidate CRN00808
Jul 03, 2017: Somatuline Auto gel 120 mg receives Japanese approval for a new indication for the treatment of gastro-entero-pancreatic neuroendocrine tumors
Jun 01, 2017: Ipsen To Present New Data of Lanreotide at ASCO
Mar 09, 2017: Ipsen announces data presentation on lanreotide (Somatuline Auto gel) at the European Neuroendocrine Tumor Society (ENETS) 2017 conference
Feb 06, 2017: Amryt Pharma Announces positive pre-clinical study results for drug compound with potential to treat acromegaly, AP102
Dec 02, 2016: Amryt Pharma provides update on AP-102
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Somatostatin Receptor Type 2 (SRIF1 or SSTR2) - Overview
Somatostatin Receptor Type 2 (SRIF1 or SSTR2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Somatostatin Receptor Type 2 (SRIF1 or SSTR2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Somatostatin Receptor Type 2 (SRIF1 or SSTR2) - Companies Involved in Therapeutics Development
Amryt Pharma plc
Crinetics Pharmaceuticals Inc
Daewoong Pharmaceutical Co Ltd
Ipsen SA
Progenics Pharmaceuticals Inc
Strongbridge Biopharma plc
Takeda Pharmaceutical Co Ltd
Zucara Therapeutics Inc
Somatostatin Receptor Type 2 (SRIF1 or SSTR2) - Drug Profiles
AP-102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CRN-00808 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CRN-01941 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Edotreotide Labeled Yttrium 90 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lanreotide acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lanreotide SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize SSTR2 and SSTR4 for Chronic Pain and Neuropathic Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize SSTR2 for Type 2 Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides to Agonize Somatostatin Receptors for Acromegaly - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
veldoreotide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
veldoreotide MR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZT-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Somatostatin Receptor Type 2 (SRIF1 or SSTR2) - Dormant Products
Somatostatin Receptor Type 2 (SRIF1 or SSTR2) - Discontinued Products
Somatostatin Receptor Type 2 (SRIF1 or SSTR2) - Product Development Milestones
Featured News & Press Releases
Jun 21, 2018: Crinetics Pharmaceuticals Awarded up to $3.2 Million in SBIR Grants for Acromegaly
Mar 12, 2018: Crinetics Pharmaceuticals Announces Upcoming Presentation on Acromegaly Drug Candiadate CRN00808 at ENDO 2018
Feb 13, 2018: Health Canada approves Ipsen Somatuline Auto gel for the treatment of carcinoid syndrome in adult patients with neuroendocrine tumors (NETs)
Feb 08, 2018: Zucara Therapeutics Receives Funding to Advance Lead Drug Candidate
Jan 15, 2018: Ipsen To Present Abstracts On lanreotide ASCO Gastrointestinal Symposium 2018
Oct 26, 2017: Crinetics Pharmaceuticals Initiates Phase 1 Study of Lead Candidate CRN00808 for Acromegaly
Sep 21, 2017: JDRF Funds Zucara Therapeutics' Approach to Preventing Hypoglycemia in People with Type 1 Diabetes
Sep 18, 2017: U.S. FDA Approves New Indication for Ipsen’s Somatuline Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome
Sep 04, 2017: Ipsen To Present Data on Somatuline at European Society of Medical Oncology congress
Jul 13, 2017: Crinetics Pharmaceuticals Awarded $2.8 Million SBIR Grant to Support Development of Acromegaly Drug Candidate CRN00808
Jul 03, 2017: Somatuline Auto gel 120 mg receives Japanese approval for a new indication for the treatment of gastro-entero-pancreatic neuroendocrine tumors
Jun 01, 2017: Ipsen To Present New Data of Lanreotide at ASCO
Mar 09, 2017: Ipsen announces data presentation on lanreotide (Somatuline Auto gel) at the European Neuroendocrine Tumor Society (ENETS) 2017 conference
Feb 06, 2017: Amryt Pharma Announces positive pre-clinical study results for drug compound with potential to treat acromegaly, AP102
Dec 02, 2016: Amryt Pharma provides update on AP-102
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indication, H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd.1), H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Amryt Pharma plc, H2 2018
Pipeline by Crinetics Pharmaceuticals Inc, H2 2018
Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2018
Pipeline by Ipsen SA, H2 2018
Pipeline by Progenics Pharmaceuticals Inc, H2 2018
Pipeline by Strongbridge Biopharma plc, H2 2018
Pipeline by Takeda Pharmaceutical Co Ltd, H2 2018
Pipeline by Zucara Therapeutics Inc, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd.1), H2 2018
Discontinued Products, H2 2018
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indication, H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd.1), H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Amryt Pharma plc, H2 2018
Pipeline by Crinetics Pharmaceuticals Inc, H2 2018
Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2018
Pipeline by Ipsen SA, H2 2018
Pipeline by Progenics Pharmaceuticals Inc, H2 2018
Pipeline by Strongbridge Biopharma plc, H2 2018
Pipeline by Takeda Pharmaceutical Co Ltd, H2 2018
Pipeline by Zucara Therapeutics Inc, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd.1), H2 2018
Discontinued Products, H2 2018
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
COMPANIES MENTIONED
Amryt Pharma plc
Crinetics Pharmaceuticals Inc
Daewoong Pharmaceutical Co Ltd
Ipsen SA
Progenics Pharmaceuticals Inc
Strongbridge Biopharma plc
Takeda Pharmaceutical Co Ltd
Zucara Therapeutics Inc
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
COMPANIES MENTIONED
Amryt Pharma plc
Crinetics Pharmaceuticals Inc
Daewoong Pharmaceutical Co Ltd
Ipsen SA
Progenics Pharmaceuticals Inc
Strongbridge Biopharma plc
Takeda Pharmaceutical Co Ltd
Zucara Therapeutics Inc
